Investigational drug · Phase 3
Olomorasib
Also called: LY3537982
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
16
Any phase or sponsor naming "Olomorasib"
First trial start
2021
Jul 19, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Olomorasib", any sponsor or status.
- Phase 112
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small-Cell Lung
- Colorectal Neoplasms
- Neoplasm Metastasis
- Urothelial Cancer
- Non-small Cell Lung Cancer
- Endometrial Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Biliary Tract Neoplasms
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Pancreatic cancer · Endometrial cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Olomorasib" as an intervention, largest first.
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06119581 · 1,264 participants (planned) · Start Dec 21, 2023 · Primary completion Nov 2027
Drug: LY3537982; Pembrolizumab and 4 more · For: Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis
Sites: Huntsville, Alabama; Gilbert, Arizona; Phoenix, Arizona · 415 sites in all
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06890598 · 700 participants (planned) · Start Mar 27, 2025 · Primary completion May 2029
Drug: Olomorasib; Pembrolizumab and 2 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Huntsville, Alabama; Mobile, Alabama; Phoenix, Arizona · 368 sites in all
- Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04956640 · 540 participants (planned) · Start Jul 19, 2021 · Primary completion Apr 2027
Drug: LY3537982; Pembrolizumab and 4 more · For: Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms and 3 more
Sites: Birmingham, Alabama; Los Angeles, California; Orange, California · 49 sites in all
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07890714 · 268 participants (planned) · Start Oct 16, 2026 · Primary completion Sep 30, 2029
Drug: Dato-DXd; Enfortumab Vedotin (EV) and 2 more · For: Urothelial Cancer; Non-small Cell Lung Cancer
Sites: Taichung, Taiwan
- A Study of Olomorasib (LY3537982) in Healthy Japanese ParticipantsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT07124013 · 191 participants · Start Sep 16, 2025 · Primary completion Jan 5, 2026
Drug: Olomorasib · For: Healthy
Sites: Fukuoka, Japan
- A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy ParticipantsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT07044271 · 120 participants · Start Jul 11, 2025 · Primary completion Nov 8, 2025
Drug: Olomorasib · For: Healthy
Sites: San Antonio, Texas; Salt Lake City, Utah
- Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLCSuspended
UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
NCT07639242 · 60 participants (planned) · Start Oct 2026 · Primary completion Jun 21, 2030
Drug: Olomorasib; Pembrolizumab · For: Lung Cancer; Lung Cancer (NSCLC); Locally Advanced NSCLC and 1 more
Sites: Chapel Hill, North Carolina
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07227025 · 60 participants (planned) · Start Mar 3, 2026 · Primary completion Nov 30, 2028
Drug: Amivantamab; Olomorasib · For: Carcinoma, Non-Small-Cell Lung
Sites: New York, New York; Fairfax, Virginia; Toronto, Canada · 12 sites in all
- A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C MutationNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07814417 · 50 participants (planned) · Start Oct 2026 · Primary completion Nov 2028
Drug: Olomorasib; Cetuximab and 3 more · For: Colorectal Neoplasms
Sites: Birmingham, Alabama; Los Angeles, California; Orlando, Florida · 18 sites in all
- A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy ParticipantsCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06719128 · 46 participants · Start Dec 6, 2024 · Primary completion Aug 25, 2025
Drug: Olomorasib · For: Hepatic Insufficiency; Healthy
Sites: Lake Forest, California; Miami, Florida; Orlando, Florida · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.
Chaft J, Lee JM, Senan S, et al. · Future Oncol 2026
- KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.
Kapoor A, Sansar B, Gupta A, et al. · Med Oncol 2026
- KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.
Rosas D, Barad P, Wright J, et al. · Int J Mol Sci 2026
- [Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions].
Nakamichi S, Kubota K · Gan To Kagaku Ryoho 2026
- Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models.
Peng S, Zhang Y, Lin X, et al. · Nat Commun 2026
- A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.
Boby JM, Ilerhunmwuwa N, Benny JM, et al. · Cancer Invest 2026
Also in development for Carcinoma, Non-Small-Cell Lung
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
- 6-Thio-2'-Deoxyguanosine6-thio-dG, THIOPhase 32 trials
Maia Biotechnology · Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small -Cell Lung
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.